Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

Presentation TCT 2025

TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial

Presenter: Mohammed Ali

October 28, 2025

Presentation TCT 2025

TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

Presenter: Grant William Reed

October 27, 2025

Presentation TCT 2025

TCT 1261: Effect of PCSK9 Inhibitors on Coronary Plaque: A Meta-Analysis and Trial Sequential Analysis

Presenter: Paulo Roberto Tartuce Filho

October 27, 2025

Presentation TCT 2024

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Presenter: Jonathan Los

October 27, 2024

Presentation TCT 2023

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

Presenter: Karol Watson

October 26, 2023

Presentation TCT 2023

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

Presenter: Sanjit Jolly

October 25, 2023

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

Presentation TCT 2022

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Marc Bonaca

September 17, 2022

Presentation TCT 2021

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Connie Hess

November 06, 2021

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

Presentation TCT 2019

Role of PCSK9 Inhibitors Post-PCI and ACS

Presenter: Marc Bonaca

September 26, 2019

News Conference News TCT 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Yael L. Maxwell

September 24, 2018

Presentation TCT 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presenter: Gregg W. Stone, Peter H. Stone, Evan A. Stein

November 01, 2017

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Presenter: Bernard J. Gersh, Felix Mahfoud, Ori Ben-Yehuda

November 01, 2016

Presentation TCT 2016

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Presenter: Bernard J. Gersh, Felix Mahfoud, Evan A. Stein

November 01, 2016

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

Presentation TCT 2015

Statin Pretreatment Prior to PCI: Are the Effects Real?

Presenter: Frederick Feit, C. Michael Gibson, Germano Di Sciascio

October 15, 2015

Presentation TCT 2015

Cilostazol: When to Consider (and Is the Data Robust?)

Presenter: Frederick Feit, C. Michael Gibson

October 15, 2015

Advertisement

TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial

TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

TCT 1261: Effect of PCSK9 Inhibitors on Coronary Plaque: A Meta-Analysis and Trial Sequential Analysis

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Role of PCSK9 Inhibitors Post-PCI and ACS

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Statin Pretreatment Prior to PCI: Are the Effects Real?

Cilostazol: When to Consider (and Is the Data Robust?)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content